(NASDAQ: OTLK) Outlook Therapeutics's forecast annual revenue growth rate of 237.46% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.61%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.34%.
Outlook Therapeutics's revenue in 2025 is $1,505,322.On average, 7 Wall Street analysts forecast OTLK's revenue for 2026 to be $1,349,287,613, with the lowest OTLK revenue forecast at $693,077,911, and the highest OTLK revenue forecast at $2,839,429,552. On average, 5 Wall Street analysts forecast OTLK's revenue for 2027 to be $3,266,212,387, with the lowest OTLK revenue forecast at $840,506,328, and the highest OTLK revenue forecast at $7,087,580,047.
In 2028, OTLK is forecast to generate $1,876,547,422 in revenue, with the lowest revenue forecast at $994,064,639 and the highest revenue forecast at $2,798,430,327.